Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03510676
NCT03510676CompletedNot Applicable

Innovative siroLimus seLf Expanding drUg-eluting Stent for the treatMent of perIpheral Disease: Evaluation of Safety aNd efficAcy. The ILLUMINA Study. (ILLUMINA)

CID - Carbostent & Implantable Devices20 sites in 3 countries100 target enrollmentStarted: January 26, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
100
Locations
20
Primary Endpoint
Primary patency (absence of clinically-driven target lesion revascularization or binary restenosis)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The aim of the prospective, multicentre, single-arm study is to assess safety and efficacy of a drug eluting stent in Nitinol alloy (NiTiDES) in term of vessel patency and composite event-free survival rate up to two years follow-up in focal/medium length lesions in patients with ischemic obstruction of superficial femoral arteries or/and proximal popliteal arteries.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient must be over 18 years inclusive at the time of consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol;
  • •A female of childbearing potential may be enrolled, provided she has a negative pregnancy test at screening;
  • •Patient has signed and dated the informed consent;
  • •Patient has symptoms of peripheral arterial disease classified as Rutherford Category (2-4); patients with Rutherford Category 2 can be included only if a conservative and/or medication therapy was unsuccessful.
  • •Patient has a resting ABI <0.9 or at exercise if resting ABI is normal; patient with incompressible arteries (ABI >1.2) at rest or at exercise must have a toe-brachial index (TBI) <0.
  • •Angiographic
  • •Patient has one documented stenotic or occluded atherosclerotic lesion (lesion length ≤ 14 cm) of the above-the-knee femoropopliteal artery, in one limb, that meet all of the inclusion criteria and none of the

Exclusion Criteria

  • •Patient has a de novo or restenotic lesion with >50% stenosis documented angiographically and no prior stent in the target lesion;
  • •The target lesion must be appropriately covered (margin of 5.0 mm on both sides of the stent) by one or two study stents (NiTiDES). Any occurred dissection of the target vessel must be treated with an additional stent (NiTiDES);
  • •Tandem lesions are allowed if the distance between 2 lesions is ≤ 3 cm and the total length of all lesions ≤ 14 cm;
  • •Guidewire successfully passed the lesion through the lumen.
  • •Exclusion Criteria:
  • •Patient is pregnant or breast-feeding;
  • •Patient is simultaneously participating in another investigational drug or device study;
  • •Patient has any planned surgical or interventional procedure within 30 days after the study procedure;
  • •Clinical conditions, disorders or allergies that limit the use of anti-platelet and/or anticoagulant therapy;
  • •Severe allergy to the contrast medium or drugs used during the procedure;
  • •Patients with known hypersensitivity or allergies to Sirolimus, fatty acids (such as stearic acid, palmitic acid, behenic acid) or the metal components of the stent (such as Nickel, Titanium and Tantalum);
  • •Serum creatinine > 2.5 mg/dl;
  • •Myocardial infarction within the 90 days prior to enrollment;
  • •Hypercoagulable state;
  • •Uncontrollable hypertension;
  • •Life expectancy < 12 months;
  • •Aneurysmal disease of abdominal aorta, iliac artery and popliteal artery;
  • •Gastrointestinal bleeding;
  • •Stroke within the 180 days prior to enrollment;
  • •Concomitant therapies such as: atherectomy, cryoplasty, scoring / cutting balloons.
  • •Angiographic
  • •Patient has significant stenosis or occlusion of inflow tract not successfully treated before this procedure;
  • •Patient has had previous stenting of target vessel;
  • •Patient lacks at least one patent vessel of runoff with <50% stenosis throughout its course;
  • •Patient has untreated angiographically-evident thrombus in the target lesion;
  • •Patients intended to be treated with more than two stents in the target lesion unless additional stent required in case of dissection;
  • •Patient intended to receive different stent from NiTiDES in target lesion;
  • •Technically unsuccessful Percutaneous Transluminal Angioplasty (PTA) procedure, for example due to the impossibility of accessing the stenotic site with a delivery system
  • •Lesions considered untreatable with PTA or other interventional techniques;
  • •Inflow lesion ≥15 cm long or occlusion (any length) in the ipsilateral Iliac artery;
  • •Not successfully treated < 15 cm long inflow lesion in the ipsilateral iliac artery [Treatment of inflow lesion must precede patient enrollment and target lesion treatment. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions];
  • •Lesions in contralateral Superficial Femoral Artery (SFA) that require intervention during the index procedure, or within 30 days after the index procedure. Lesions in contralateral SFA can be treated either >30 days prior to or > 30 days after the index procedure;
  • •Patient with stenosis adjacent to an aneurysmal lesion of diameter at least twice the lumen of the native vessel;
  • •Lesions localized in the two distal thirds of the popliteal artery (or at the knee joint, generally considered).
  • •Patients under judicial protection, tutorship or curatorship (for France only).

Outcomes

Primary Outcomes

Primary patency (absence of clinically-driven target lesion revascularization or binary restenosis)

Time Frame: 12 months after procedure

Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis; binary restenosis is defined as a peak systolic velocity ratio (PSVR) \>2.4 (duplex evaluation)

Event-free survival rate from Major Adverse Events

Time Frame: 12 months after procedure

Freedom from Clinical Events Committee (CEC) adjudicated Major Adverse Event (death, target limb amputation, target limb ischemia requiring surgical intervention or surgical repair of target vessel or clinically-driven target lesion revascularization) or worsening of the Rutherford score by 2 classes, or to class 5 or 6.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
CID - Carbostent & Implantable Devices
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (20)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery DiseaseCoronary Artery Disease
NCT05205499Biotyx Medical (Shenzhen) Co., Ltd.1,059
Recruiting
Not Applicable
IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive DiseaseCritical Limb Ischemia (CLI)
NCT04849325Biotyx Medical (Shenzhen) Co., Ltd.120
Completed
Early Phase 1
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell TransplantationStem Cell Transplantation
NCT00612274Yale University26
Terminated
Not Applicable
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery LesionsCoronary Atherosclerosis
NCT00606333Cordis Corporation394
Completed
Phase 4
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis TrialCoronary Artery Disease
NCT00497172Cordis Corporation150
The ILLUMINA Study. (ILLUMINA) | Clinical Trial